Tag: Myeloproliferative disorders

While long-term hydroxyurea therapy is effective for managing conditions like sickle cell disease and myeloproliferative disorders, an estimated 10-20% of patients may be intolerant or resistant to treatment. Knowing when to discontinue hydroxyurea is crucial for patient safety, as this decision is based on monitoring for severe side effects, treatment efficacy, and specific patient conditions.

Hydroxyurea is a crucial, long-term therapy for numerous hematologic conditions, including sickle cell disease and certain myeloproliferative neoplasms. While effective, understanding what are the long-term effects of taking hydroxyurea is essential for patients, as the medication is associated with several serious health issues over time, including myelosuppression and an increased cancer risk.

For many people with chronic conditions like sickle cell disease, hydroxyurea is a long-term therapy, and some individuals have used it safely and effectively for over 15 years. The question, 'how many years can you take hydroxyurea?' does not have a single answer, as duration depends heavily on the individual's condition, response to treatment, and managing potential side effects in collaboration with a healthcare provider.